93 related articles for article (PubMed ID: 23651827)
1. Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation.
Cangemi R; Pignatelli P; Carnevale R; Corazza GR; Pastori D; Farcomeni A; Basili S; Davì G; Ferro D; Hiatt WR; Licata G; Lip GY; Loffredo L; Mannucci PM; Vestri A; Violi F;
Int J Cardiol; 2013 Oct; 168(4):3241-7. PubMed ID: 23651827
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation.
Ferro D; Loffredo L; Polimeni L; Fimognari F; Villari P; Pignatelli P; Fuster V; Violi F
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2763-8. PubMed ID: 17901373
[TBL] [Abstract][Full Text] [Related]
3. Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients.
Perri L; Pastori D; Pignatelli P; Violi F; Loffredo L
Int J Cardiol; 2015 Jan; 179():139-43. PubMed ID: 25464433
[TBL] [Abstract][Full Text] [Related]
4. Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation.
Pignatelli P; Pastori D; Carnevale R; Farcomeni A; Cangemi R; Nocella C; Bartimoccia S; Vicario T; Saliola M; Lip GY; Violi F
Thromb Haemost; 2015 Mar; 113(3):617-24. PubMed ID: 25392853
[TBL] [Abstract][Full Text] [Related]
5. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
6. [The impact of hypertension history and baseline blood pressure levels on the cardiovascular outcomes in Chinese emergency atrial fibrillation patients].
Wang J; Yang YM; Zhu J; Zhang H; Shao XH; Tian L; Huang B
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Nov; 41(11):911-5. PubMed ID: 24370216
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
[TBL] [Abstract][Full Text] [Related]
8. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
[TBL] [Abstract][Full Text] [Related]
9. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.
Olesen JB; Lip GY; Lane DA; Køber L; Hansen ML; Karasoy D; Hansen CM; Gislason GH; Torp-Pedersen C
Am J Med; 2012 Aug; 125(8):826.e13-23. PubMed ID: 22579139
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.
Krishnamoorthy S; Khoo CW; Lim HS; Lane DA; Pignatelli P; Basili S; Violi F; Lip GY
Eur J Clin Invest; 2013 Oct; 43(10):1032-8. PubMed ID: 23961715
[TBL] [Abstract][Full Text] [Related]
11. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.
Banerjee A; Taillandier S; Olesen JB; Lane DA; Lallemand B; Lip GY; Fauchier L
Int J Cardiol; 2013 Sep; 167(6):2682-7. PubMed ID: 22795403
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of vitamin E are associated with early recurrence of atrial fibrillation after electric cardioversion.
Ferro D; Franciosa P; Cangemi R; Carnevale R; Pignatelli P; Loffredo L; Perri L; Catasca E; Violi F
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):327-33. PubMed ID: 22362890
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
14. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
15. Mortality and cause of death in patients with chronic non-rheumatic atrial fibrillation after a two-year follow-up.
Scardi S; Mazzone C; Pandullo C; Goldstein D; Di Lenarda A; Chersevani D
G Ital Cardiol; 1999 Jun; 29(6):637-46. PubMed ID: 10396667
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
17. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation.
Nakagawa K; Hirai T; Takashima S; Fukuda N; Ohara K; Sasahara E; Taguchi Y; Dougu N; Nozawa T; Tanaka K; Inoue H
Am J Cardiol; 2011 Mar; 107(6):912-6. PubMed ID: 21247518
[TBL] [Abstract][Full Text] [Related]
18. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.
Genovesi S; Vincenti A; Rossi E; Pogliani D; Acquistapace I; Stella A; Valsecchi MG
Am J Kidney Dis; 2008 Feb; 51(2):255-62. PubMed ID: 18215703
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of atrial tachyarrhythmias in patients with interatrial block.
Ariyarajah V; Fernandes J; Kranis M; Apiyasawat S; Mercado K; Spodick DH
Int J Cardiol; 2007 Jun; 118(3):332-7. PubMed ID: 17027099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
